IRS1/2 pharmacological inhibition in primary MPN samples reduced cell viability in JAK2V617F-positive but not JAK2WT specimens; combination with ruxolitinib had additive effects. This evidence concerns the gene IRS1 and myeloproliferative neoplasm.